GLP-1 receptor agonists do not appear to suppress male reproductive hormones in healthy men, and may improve testosterone and semen parameters in obese men with hypogonadism — here is what the ENDO 2026 research shows. ...
Dr. Norena Velasquez[/caption]
MedicalResearch.com Interview with:
Jairo Norena Velasquez, MD
Associate Division Chief, Endocrinology Division
Alameda Health System
Oakland, California
Response: Type 2 diabetes is associated with a paradoxically elevated fracture risk — up to three times higher than the general population — despite normal or even elevated bone mineral density. The underlying problem is poor bone quality driven by chronic hyperglycemia, advanced glycation end-product accumulation, and increased cortical porosity. Compounding this, intentional weight loss — a cornerstone of diabetes treatment — can accelerate bone loss by reducing mechanical loading on the skeleton.
Semaglutide is one of the most effective weight-loss agents available, yet direct real-world comparisons of its skeletal effects against other active weight-loss therapies were lacking.
Using the Atropos Health Eos EHR database — 161 million US patients from 2016 to 2023 — we compared fracture incidence and BMI change in adults with type 2 diabetes initiating semaglutide versus dulaglutide, phentermine/topiramate, or bupropion/naltrexone, using high-dimensional propensity score matching (17,506 pairs per group).
Semaglutide was associated with greater weight loss (mean delta BMI −1.9 vs. −1.2 kg/m²; difference −0.72 kg/m², p < 0.001) and a 15% reduction in fracture incidence (HR 0.85, 95% CI 0.77–0.93; p < 0.001) over a mean follow-up of 3.6 years.